Century Therapeutics (IPSC)CEO bought ~$30K
Brent Pfeiffenberger, CEO at Century Therapeutics, bought ~$30K of Century Therapeutics shares.
- ~$30K
- Approx. value · 52K sh @ $0.5837
- 3.32M
- Holds after · shares reported
- Traded
- Dec 12, 2025
- Filed
- Dec 16, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Nov 3, 2025InsiderOfficer sold ~$171 of IPSC shares in the open market
- Nov 13, 2025Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors (and 1 more item)
- Nov 17, 2025InsiderCEO sold ~$15K of IPSC shares in the open market
- Nov 19, 2025Insider · First insider buy since Sep 2024CEO purchased ~$17K of IPSC shares in the open market
- Nov 20, 2025InsiderOfficer sold ~$2.7K of IPSC shares in the open market
- Dec 8, 2025Insider · 2 peopleInsiders: 2 sales (~$417)
- Dec 9, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On December 9, 2025, the Board of Directors (the “Board”) of Century Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from six to eight directors and appointed Dr. Martin Murphy and Dr. Han Lee as directors of the Board, effective as of December 9, 2025 (the “Effective Date”).”
- Dec 12, 2025 · this disclosureInsider · 6 days before an 8-KCEO purchased ~$30K of IPSC shares in the open market
What came next
- Dec 18, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 18, 2025, Carlo Rizzuto, Ph.D. notified the board of directors (the “Board”) of Century Therapeutics, Inc. (the “Company”) of his intent to resign from the Board, effective December 18, 2025.”
- Dec 22, 2025Insider · Their first buy on recordOfficer purchased ~$49K of IPSC shares in the open market
- Jan 7, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
- Feb 3, 2026InsiderOfficer sold ~$589 of IPSC shares in the open market
- Mar 9, 2026Insider · 2 peopleInsiders: 2 sales (~$2K)
- Mar 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
- Mar 12, 2026Insider · 2 peopleInsiders: 2 sales (~$44K)
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Century Therapeutics
For Century Therapeutics, OQRO holds 5 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IPSC page.
Other recent filings by Brent Pfeiffenberger, President and CEO
- SEC Form 4 at Century Therapeutics (IPSC)Nov 20, 2025
- SEC Form 4 at Century Therapeutics (IPSC)Nov 19, 2025
- SEC Form 4 at Century Therapeutics (IPSC)Sep 10, 2025
- SEC Form 4 at Century Therapeutics (IPSC)Jun 11, 2025
- SEC Form 4 at Century Therapeutics (IPSC)May 20, 2025
The full history of Brent Pfeiffenberger, President and CEO is on the profile page.
How this filing works
Other disclosures at Century Therapeutics
- SEC Form 4Sep 15, 2026
- SEC Form 4Sep 15, 2026
- SEC Form 4Sep 9, 2026
- SEC Form 4Sep 9, 2026
- SEC Form 4Aug 5, 2026
- SEC Form 4Jun 15, 2026
Everything OQRO holds on this company is on its IPSC page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
